|
| Practices regarding nonresponse to treatment | Number | Percent |
|
| Time of suspecting nonresponse to treatment () | | |
| Within three months of initiation of therapy | 45 | 90.0 |
| After four or more months of therapy | 5 | 10.0 |
|
| Action taken when nonresponse is suspected () | | |
| Advise sputum culture and drug sensitivity test | 35 | 60.3 |
| Advise HIV test | 26 | 44.8 |
| Prescribe another regimen | 23 | 39.7 |
| Refer the patient | 6 | 10.3 |
| Assess compliance and related reasons of nonresponse | 6 | 10.3 |
| Extension of intensive phase | 1 | 1.7 |
|
| Time of requesting sputum culture and drug sensitivity for rifampicin in cases suspected for presence of drug-resistance () | | |
| After one month of treatment with first regimen (too early) | 3 | 6.0 |
| After two or three months of treatment with first regimen# | 24 | 48.0 |
| After nonresponse to second regimen (too late) | 23 | 46.0 |
|
| Conditions when drug-resistance is suspected at beginning of treatment () | | |
| Contact with a case of drug-resistance TB# | 21 | 67.7 |
| Coinfection with HIV | 10 | 32.3 |
| History of previous treatment for TB# | 4 | 12.9 |
|
| Basis of diagnosis of drug-resistant TB () | | |
| Including bacteriological test | 48 | 94.1 |
| Bacteriological and clinical | 30 | 58.8 |
| Bacteriological, clinical, and radiological | 14 | 27.5 |
| Bacteriological alone | 3 | 5.9 |
| Bacteriological and radiological | 1 | 2.0 |
| Excluding bacteriological test | 3 | 5.9 |
| Clinical alone | 1 | 2.0 |
| Clinical and radiological | 2 | 3.9 |
|
